Injectable extended-release naltrexone for opioid dependence

The Lancet

Volumn 378, Issue 9792, 2011, Pages 665-666

  Throckmorton, Douglas C ^a   Temple, Robert ^a   Rappaport, Bob A ^a   Roca, Rigoberto ^a   Winchell, Celia J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; NALTREXONE; NARCOTIC ANTAGONIST;

CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; OPIATE ADDICTION; PRIORITY JOURNAL; RELAPSE; STANDARD; UNITED STATES; DELAYED RELEASE FORMULATION; INJECTION; NOTE;

DELAYED-ACTION PREPARATIONS; DRUG APPROVAL; HUMANS; INJECTIONS; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80051972499     PISSN: 0140-6736     EISSN: 1474-547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61332-9     Document Type: Letter

References (3)

1. D Wolfe, MP Carrieri, N Dasgupta, A Wodak, R Newman, RD Bruce Concerns about injectable naltrexone for opioid dependence Lancet 377 2011 1468 1470
2. US Food and Drug Administration Meeting of the Psychopharmacologic Drugs Advisory Committee http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ ucm225655.pdf September 16, 2010 (accessed Aug 9, 2011).
3. US Food and Drug Administration 2010 meeting materials, Psychopharmacologic Drugs Advisory Committee http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ PsychopharmacologicDrugsAdvisoryCommittee/ucm221387.htm (accessed May 9, 2011).